HTG Molecular Diagnostics Participating in WIN 2017 Symposium
TUCSON, Ariz., June 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced its participation in WIN 2017 Symposium, dedicated to Expediting Global Innovation in Precision Cancer Medicine, which is being held in Paris, France on June 26 and 27, 2017. HTG is an industry member of the Worldwide Innovative Networking (WIN) Consortium, whose mission is to rapidly translate personalized cancer medicine discoveries into standards of patient care worldwide. WIN is a non-profit global network of world-class academics, industries and patients’ advocates aiming to transform the practice of oncology and significantly improve survival and quality of life of cancer patients. HTG was actively recruited to the consortium to support gene expression profiling activities of its members, including WIN clinical trials that integrate RNA investigations in the clinical setting.
- Press Releases
- WIN Symposium